You are here:Home-Chemical Inhibitors & Agonists-Cell Cycle/DNA Damage-Aurora Kinase-Ilorasertib
Ilorasertib

Chemical Structure : Ilorasertib

CAS No.: 1227939-82-3

Ilorasertib (ABT-348, ABT348)

Catalog No.: PC-21147Not For Human Use, Lab Use Only.

Ilorasertib (ABT-348) is a potent inhibitor of Aurora kinases as well as the VEGF and PDGF families of receptor tyrosine kinases (Aur B IC50=2 nM, PDGFRβ IC50=3 nM).

Packing Price Stock Quantity
5 mg $228 In stock
10 mg $378 In stock
25 mg $588 In stock
100 mg Get quote
1 g Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

Biological Activity

Ilorasertib (ABT-348) is a potent inhibitor of Aurora kinases as well as the VEGF and PDGF families of receptor tyrosine kinases (Aur B IC50=2 nM, PDGFRβ IC50=3 nM).
Ilorasertib (ABT-348) inhibits phosphorylation of histone H3, induces of polyploidy, and inhibits proliferation of a variety of leukemia, lymphoma, and solid tumor cell lines (IC(50) = 0.3-21 nM).
Ilorasertib (ABT-348) shows potent binding activity (K(i) < 30 nM) against VEGFR/PDGFR families and the Src family of cytoplasmic tyrosine kinases.
Ilorasertib (ABT-348) inhibits VEGFR/PDGFR autophosphorylation in cells and inhibition of VEGF-stimulated endothelial cell proliferation (IC(50) ≤ 0.3 nM).
Ilorasertib (ABT-348) exhibits antiproliferative activity against BCR-ABL chronic myeloid leukemia cells and cells expressing the gleevec-resistant BCR-ABL T315I mutation.
Ilorasertib (ABT-348) demonstrates significant antitumor efficacy in representative solid tumor [HT1080 and pancreatic carcinoma (MiaPaCa), tumor stasis] and hematological malignancy (RS4;11, regression) xenografts.

Physicochemical Properties

M.Wt 488.54
Formula C25H21FN6O2S
Appearance Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

N-[4-[4-Amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl]phenyl]-N′-(3-fluorophenyl)urea

References

1. Glaser KB, et al. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27.

2. Curtin ML, et al. Bioorg Med Chem Lett. 2012 Jul 15;22(14):4750-5.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: